Kadimastem Ltd.

Feb 25, 2025

Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment

Feb 10, 2025

NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies

Jan 31, 2025

Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics

Jan 16, 2025

Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS

Dec 30, 2024

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger